Claims
- 1. A derivative of a 4-oxo-2-butenoic acid having the property of anti-myeloma activity, wherein said derivative is selected from the group consisting of:4-(4-Chloro-phenyl)-2-(N′-fluoren-9-ylidene-hydrazino)-4-oxo-but-2-enoic acid methyl ester: 2-{N′-[(2-Bromo-phenyl)-phenyl-methylene]-hydrazino}-4-oxo-4-phenyl-but-enoic acid methyl ester; 2-{N′-[(4-Dimethylamino-phenyl)-phenyl-methylene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester; and -2-{N′-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester.
- 2. A method of treating myeloma in a human being in need of such treatment, comprising administering to said human being one or more derivatives of 4-oxo-2-butenoic acid according to claim 1.
Parent Case Info
This invention claims the benefit of priority of U.S. Provisional Application Serial No. 60/296,823 filed Jun. 8, 2001.
US Referenced Citations (11)
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/296823 |
Jun 2001 |
US |